Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose—the PP100–01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial

Abstract Background Paracetamol (acetaminophen) overdose (POD) is the commonest cause of acute liver failure in Europe and North America. Current treatment involves the use of the antidote N-acetylcysteine (NAC) in patients deemed at risk of liver damage. This regimen was introduced in the 1970s and...

Full description

Bibliographic Details
Published in:Trials
Main Authors: The POP Trial Investigators, James Dear
Format: Article
Language:English
Published: BMC 2019-01-01
Subjects:
Paracetamol
Acetylcysteine
Overdose
Hepatotoxicity
Calmangafodipir
Online Access:http://link.springer.com/article/10.1186/s13063-018-3134-1

Internet

http://link.springer.com/article/10.1186/s13063-018-3134-1

Similar Items